JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue

JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)

An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Transdermal Drug Delivery for Migraine Management: Polymer-Based Patch Design, Skin Permeation Enhancement, and Safety Considerations

Ms. Alfiya S Mulani[1], Ms. Pratiksha R Ravankole[2], Dr. Sampat Navale[3]

[1]Final Year Bachelor of Pharmacy Student, AAEMF's Delight College of Pharmacy, Koregaon Bhima, Pune, Maharashtra, India-412216

[2]Assistant Professor, Department of Pharmaceutical Chemistry, AAEMF's Delight College of Pharmacy, Koregaon Bhima, Pune, Maharashtra, India-412216

[3]Principal, Department of Pharmacognosy, AAEMF's Delight College of Pharmacy, Koregaon Bhima, Pune, Maharashtra, India-412216

Abstract:

Migraine is a common neurological condition marked by repeated headache attacks and symptoms such as nausea, sensitivity to light, and sensitivity to sound. These episodes can interfere substantially with daily activities and quality of life. Although oral medicines are widely used, they may not always be ideal because migraine itself can cause gastrointestinal problems, drug absorption can vary, and maintaining consistent drug levels may be difficult. Transdermal drug delivery systems, which deliver medication through the skin, may offer an alternative for certain migraine treatments. This review explores the potential of polymer-based transdermal patches, focusing on the choice of polymers, patch design, drug–polymer compatibility, and controlled release of medication. It also considers methods used to improve drug movement across the skin, including chemical permeation enhancers and physical techniques, along with their benefits, limitations, and possible effects on skin health. Safety remains an important consideration in patch development. Factors such as skin irritation, allergic reactions, systemic side effects, product stability, adhesion, and patient comfort can all influence whether a transdermal system is suitable for regular use. The review also highlights formulation challenges, drug-specific requirements, and the importance of thorough preclinical and clinical testing. Polymer-based transdermal patches represent a promising area of research for delivering suitable migraine medicines. However, their clinical value will depend on the properties of the drug, the quality of the formulation, sufficient skin permeation, and an acceptable safety profile. Further formulation research and well-designed clinical studies are needed to determine their effectiveness in migraine management.

Keywords: Migraine; Transdermal Drug Delivery System; Polymeric Patch; Skin Permeation Enhancers; Controlled Drug Release; Safety Evaluation.

1. INTRODUCTION:

Migraine is a common and disabling neurological disorder marked by recurring headaches that range from moderate to severe. Attacks are often accompanied by nausea, vomiting, sensitivity to light (photophobia), and sensitivity to sound (phonophobia). The pain is commonly described as pulsating and affecting one side of the head, although some people experience pain on both sides. Affecting around 15% of the global population, migraine is a major public health concern because it can significantly disrupt everyday life and reduce quality of life.[1]

Migraine involves several complex neurological processes. One important mechanism is the activation of the trigeminovascular system, along with changes in the way the brain processes pain. Calcitonin gene-related peptide (CGRP) also has a key role in transmitting migraine-related pain. Typical symptoms include a throbbing headache, nausea, vomiting, and increased sensitivity to light and sound. Some individuals may also experience visual or sensory disturbances known as aura. If left untreated or not managed adequately, a migraine attack can last for up to 72 hours.

Common treatments for migraine include non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, as well as triptans, including sumatriptan and rizatriptan. Oral medicines are widely used, but they may be less effective during an acute attack because nausea and vomiting can make it difficult to take or retain medication. In addition, gastrointestinal absorption and presystemic metabolism can reduce the amount of drug that reaches the bloodstream. These limitations have led researchers to explore alternative methods of drug delivery. [1,3]

Transdermal drug delivery systems (TDDS) deliver medicines through the skin and into the bloodstream. Because they avoid the gastrointestinal tract, they may overcome issues related to gastrointestinal absorption and first-pass metabolism in the liver.

Polymer-based patches are generally made from film-forming polymers, drug-containing matrices, adhesives, and other excipients. Together, these components help control drug release and ensure that the patch remains in close contact with the skin.

A major challenge in transdermal delivery is the stratum corneum, the outermost layer of the skin, which acts as a strong barrier to drug penetration. For this reason, selecting appropriate polymers and using

effective permeation-enhancement methods are important steps in developing a successful patch formulation. Polymer-based transdermal patches may be particularly useful for migraine patients who experience nausea and vomiting during acute attacks and may struggle to take oral medication. Earlier studies have explored transdermal delivery of sumatriptan and the use of techniques such as iontophoresis to improve drug transport across the skin. However, issues such as skin irritation, inconsistent drug permeation, and limited clinical evidence still need to be addressed. This review therefore examines polymer-based patch design, the selection of drugs and polymers, methods for enhancing skin permeation, formulation evaluation, and safety considerations for transdermal migraine management. [2,3]

2. MIGRAINE:

2.1 Overview and Pathophysiology of Migraine.

Migraine is a complex neurological disorder linked to changes in brain excitability and the way sensory information is processed. Genetic factors may make some individuals more susceptible to migraine. In addition, an imbalance between excitatory and inhibitory activity in the brain can contribute to the onset of an attack. These changes may heighten sensitivity to sensory stimuli and make it easier for pain-related pathways to become activated. [4,5]

Cortical spreading depression (CSD) is a slow-moving wave of intense activity in neurons and glial cells, followed by a temporary reduction in normal brain activity. It is believed to be an important mechanism behind migraine aura, which can cause short-term visual or sensory changes before or during a migraine attack. CSD may also activate the trigeminovascular system, linking changes in the brain's cortex to the development of migraine pain. [4,6]

The trigeminovascular system has a central role in transmitting migraine pain. When sensory nerve endings from the trigeminal nerve that supply the meninges are activated, they send pain signals to the brainstem and other higher brain regions involved in pain processing. Increased sensitivity within these pathways can contribute to persistent headache and cutaneous allodynia, a condition in which normally harmless sensations, such as touching the skin or brushing the hair, become painful during a migraine attack. [4,5]

Calcitonin gene-related peptide (CGRP) is an important neuropeptide involved in the development of migraine. It contributes to trigeminal nerve signalling, pain transmission, and widening of blood vessels. Evidence supporting its role in migraine has led to the development of CGRP-targeted treatments. However, migraine is a complex neurological disorder, and its development cannot be explained by vascular changes alone. [5]

Activation of trigeminal sensory pathways can trigger the release of neuropeptides and other signalling molecules around the meninges. These processes may lead to neurogenic inflammation and increased sensitivity in both peripheral and central pain pathways. As a result, patients may experience more intense headache pain, sensitivity to light (photophobia), and allodynia, where normally harmless stimuli become painful. The interaction between cortical activity, trigeminal nerve signalling, and central pain regulation contributes to the complex nature of migraine. [4,5]

2.2 Convectional treatment Approaches:

2.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Analgesics.

Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and diclofenac, are commonly used to treat mild-to-moderate migraine attacks. They work by blocking cyclooxygenase enzymes, which reduces the production of prostaglandins involved in pain and inflammation. Paracetamol may also be appropriate for some patients. However, NSAIDs can cause gastrointestinal side effects and should be used carefully in people with kidney or cardiovascular conditions. [7,8]

2.2.2 Triptans.

Triptans, such as sumatriptan, rizatriptan, zolmitriptan, and eletriptan, are migraine-specific medicines used to treat acute attacks. They are often prescribed when NSAIDs do not provide enough relief or when an attack is moderate to severe. Triptans mainly act on serotonin 5-$HT_1B/_1D$ receptors and help reduce trigeminal pain signalling. Although they are effective for many people, they are not suitable for everyone, especially patients with certain cardiovascular or cerebrovascular conditions. [7,9]

2.2.3 Antiemetics and Other Treatment Options.

Nausea and vomiting are common during migraine attacks and can make it difficult to take or keep down oral medicines. Antiemetics, such as metoclopramide and domperidone, may help control these symptoms and improve tolerance of treatment. For patients who cannot take oral medication, alternative options, including intranasal sprays and subcutaneous injections, may be considered. [7,10]

2.2.4. Need for Alternative Drug-Delivery Systems.

Transdermal drug delivery is being explored as an alternative route for certain migraine medicines because it can avoid gastrointestinal absorption and first-pass metabolism in the liver. Polymer-based patches can be formulated to release drugs in a controlled manner while remaining in close contact with the skin. However, their success depends on factors such as the drug's physicochemical properties, its ability to pass through the skin, the overall formulation design, and safety. Further formulation research and clinical studies are therefore needed before polymer-based patches can be established as a practical option for migraine management. [2]

2.3Limitations of Conventional Drug Delivery:

2.3.1. Delayed and Variable Drug Absorption.

Oral medication is the most common approach for treating migraine, but its effectiveness can be reduced during an attack. Delayed gastric emptying and other gastrointestinal disturbances may slow down or make drug absorption unpredictable. As a result, the medicine may take longer to work or may not provide adequate pain relief when it is needed most. [1,7]

2.3.2. Nausea and Vomiting.

Nausea and vomiting are common during migraine attacks and can make oral treatment difficult. Severe nausea may make it hard for patients to swallow tablets, while vomiting can prevent the medicine from being retained long enough to work. This can reduce the convenience of treatment and lead to delayed or missed doses. For some patients, alternative non-oral drug delivery methods may therefore be more suitable. [1,13]

2.3.3. First-Pass Metabolism and Limited Bioavailability.

Some anti-migraine medicines undergo presystemic metabolism after they are taken orally, meaning that part of the drug is broken down before it reaches the bloodstream. The extent of this effect varies depending on the drug and its pharmacokinetic properties. As a result, the oral bioavailability of certain migraine medicines may be reduced, which can affect how well they work. Transdermal delivery is being explored as an alternative because it can avoid gastrointestinal absorption and first-pass metabolism in the liver. [7,13]

2.3.4 Adverse Effects and Limitations of Alternative Conventional Routes.

Although non-oral options such as intranasal sprays and injections can be helpful when oral medication is not suitable, they also have drawbacks. Nasal sprays may cause an unpleasant taste or irritation inside the nose, while injections can be painful, uncomfortable, and inconvenient for some patients. In addition, triptans are not appropriate for people with certain cardiovascular or cerebrovascular conditions. The choice of formulation should therefore be based on the patient's individual needs, associated symptoms, and the safety profile of the medicine. [7,14]

3. TRANSDERMAL DRUG DELIVERY SYSTEM FOR MIGRAINE MANAGEMENT:

3.1 Basic principle of TDDS:

Transdermal drug delivery systems (TDDS) are designed to deliver medicines through the skin and into the bloodstream, where they can produce a therapeutic effect. After a patch is applied, the drug is released from the formulation and enters the stratum corneum, the outermost layer of the skin. It then moves through the skin by passive diffusion or with the help of assisted transport methods before reaching the small blood vessels in the dermis. The rate at which the drug is delivered depends on several factors, including its concentration, molecular characteristics, ability to penetrate the skin, and the composition of the patch. [1,14]

3,2 Role of the Skin Barrier.

The stratum corneum is the main barrier to transdermal drug delivery because its tightly organized lipid structure limits the entry of many medicines. For a drug to reach deeper skin layers, its molecules must first enter and diffuse through this outer layer. Its ability to do so is influenced by properties such as molecular size, lipophilicity, solubility, and the concentration gradient across the skin. To improve drug transport, transdermal systems may include chemical permeation enhancers or use physical methods that help medicines pass through the skin more effectively. [14,15]

3.3 Structure and components of a Transdermal Patch: Structure of a Transdermal Patch.

A transdermal patch is a multilayered dosage form that delivers medicine through the skin and into the bloodstream. It usually includes a backing layer, a drug-containing matrix or reservoir, an adhesive layer, and a protective release liner. Depending on the design, the patch may also contain a rate-controlling membrane and excipients such as plasticizers or permeation enhancers. The way these components are arranged affects the patch's strength and flexibility, ability to adhere to the skin, drug-release pattern, and overall delivery performance. [16,17]



Fig 1- Structure of Transdermal patch.

3.3.1 Components of a Transdermal Patch:

3.3.1.1. Backing Layer. The backing layer is the outermost protective part of a transdermal patch. It protects the drug-containing formulation from moisture, contamination, and other environmental factors, while also giving the patch strength and flexibility. Materials such as polyethylene, polyester, and polypropylene may be selected depending on the needs of the formulation. [16,17]

3.3.1.2. Drug Reservoir or Polymer Matrix. The drug reservoir or polymer matrix is the part of a transdermal patch that contains the active pharmaceutical ingredient. In matrix-type patches, the drug is dissolved or dispersed throughout a polymer system. In reservoir-type patches, the drug is held in a separate formulation, usually with a rate-controlling membrane between the drug reservoir and the skin. Polymers help keep the formulation stable and also influence how the drug is released from the patch. Common polymers used in transdermal formulations include hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and ethyl cellulose, depending on the desired properties of the patch. [15,16]

3.3.1.3. Pressure-Sensitive Adhesive. The adhesive layer keeps the patch firmly attached to the skin for the intended period of use. It should provide sufficient adhesion while minimizing irritation or discomfort when the patch is applied or removed. Common materials used for this purpose include polyacrylates, silicones, and polyisobutylenes. In drug-in-adhesive patches, the medicine is incorporated directly into the adhesive layer. [16,17]

3.3.1.4. Rate-Controlling Membrane. A rate-controlling membrane is commonly used in reservoir-type transdermal patches. It regulates how the drug moves from the reservoir toward the skin and helps control the rate of drug release. Materials such as ethylene-vinyl acetate and certain polyurethane membranes may be chosen based on the formulation design. However, not every transdermal patch requires this component. [16,17]

3.3.1.5. Permeation Enhancers and Plasticizers. Permeation enhancers may be added to selected formulations to help medicines pass through the stratum corneum more effectively. Common examples include propylene glycol, ethanol, and certain fatty acids. Plasticizers, such as polyethylene glycol or triethyl citrate, can be used in suitable formulations to make polymer films more flexible and less brittle. The choice and amount of these ingredients should be based on drug–excipient compatibility, patch performance, and skin tolerability. [16,17]

3.4. Mechanism of drug transport through skin:

3.4.1. Intercellular Pathway.

The intercellular route is the main pathway through which many drugs pass across the stratum corneum. In this route, drug molecules move through the lipid-rich spaces between the corneocytes, which are the cells of the outermost skin layer. Before reaching the deeper layers of the skin, the drug must follow a long and winding path through this intercellular lipid matrix. How effectively a drug moves by this route depends mainly on its physicochemical properties, especially its molecular size, lipid solubility, and ability to partition into the skin. [15,18]

3.4.2. Transcellular Pathway.

In the transcellular route, drug molecules pass directly through the corneocytes and their cell membranes. As they move through the skin, they encounter alternating water-loving and lipid-rich environments, which can make transport more difficult. Effective movement through this pathway therefore depends on the drug's ability to enter and diffuse through both aqueous and lipid regions. Factors such as molecular size, solubility, and partitioning behavior influence how efficiently a drug can permeate by the transcellular route. [15,18]

3.4.3. Trans Appendageal Pathway.

The transappendageal route, also called the shunt pathway, allows drugs to enter the skin through structures such as hair follicles, sebaceous glands, and sweat ducts. These appendages can provide alternative routes that partly bypass the stratum corneum barrier. This pathway may be useful for certain polar or ionized drugs and for specialized systems, including nanoparticle-based formulations. However, because these skin structures cover only a small part of the total skin surface, their contribution to drug permeation in conventional transdermal systems is generally limited. [15,19]

3.5. Advantages and Limitations of TDDS:

3.5.1. Advantages.

Transdermal drug delivery systems (TDDS) have several advantages over conventional oral medicines. They are non-invasive, convenient to use, and can be designed to release a drug in a controlled manner. By delivering medicine through the skin, they can avoid gastrointestinal degradation and first-pass metabolism in the liver, which may improve the bioavailability of suitable drugs. Sustained delivery may also help maintain more consistent drug levels in the bloodstream and reduce how often medication needs to be taken. In addition, a patch can be removed when treatment needs to stop, although drug that has already entered the skin or bloodstream may continue to have an effect for some time. [15,17]

For migraine management, transdermal delivery may be especially useful for patients who experience nausea or vomiting and find it difficult to take or retain oral medication. It can also offer an alternative route for drugs with properties that allow them to pass through the skin effectively. However, the success of a migraine patch depends on the specific drug, formulation, and delivery technology. These benefits cannot be assumed for every anti-migraine medicine. [17,20]

3.5.2. Limitations.

Despite these advantages, transdermal drug delivery systems have important limitations. The stratum corneum, the outermost layer of the skin, acts as a major barrier and restricts the penetration of many drugs. Conventional patches are generally best suited to medicines with an appropriate molecular size, high potency, suitable solubility, and the ability to partition into the skin. Therefore, large molecules and drugs that require high doses can be difficult to deliver through passive transdermal systems. [15,17]

Other limitations include skin irritation, redness, itching, and contact dermatitis caused by the drug, adhesive, or permeation enhancers. Drug absorption may also vary depending on the application site, skin condition, patch adhesion, and individual skin characteristics. In addition, transdermal patches may have a slower onset of action than some conventional formulations, making them less suitable when rapid drug delivery is needed. Although chemical enhancers and physical techniques can improve skin permeation, they may also introduce additional formulation, safety, or device-related challenges. [15,17,21]

4. POLYMER-BASED TRANSDERMAL PATCH DESIGN:

4.1 Types of Transdermal Patches:

Transdermal patches are designed to deliver medicines through the skin and into the bloodstream. They are mainly classified according to where the drug is located within the patch and how its release is controlled. The major types are drug-in-adhesive, matrix-type, reservoir-type, and membrane-controlled patches. Selecting the most suitable system depends on the drug's physicochemical properties, the required release rate, the characteristics of the polymer, and the intended duration of treatment. [16,17]

4.1.1. Drug-in-Adhesive Patches.

In drug-in-adhesive (DIA) patches, the drug is incorporated directly into a pressure-sensitive adhesive polymer. The patch usually consists of a backing layer, a drug-containing adhesive layer, and a removable release liner. In single-layer designs, the adhesive

has two roles: it keeps the patch attached to the skin and holds the drug. Multilayer systems may include more than one drug-containing adhesive layer.

After the patch is applied, the drug diffuses from the adhesive toward the skin. It then partitions into the stratum corneum and permeates through the deeper layers of the skin. The rate of release depends on the drug concentration, solubility, and diffusivity within the adhesive, as well as its interaction with the skin.

A key limitation of DIA patches is that the drug can affect the adhesive's tack, cohesion, and stability. Drug loading may also be restricted by limited solubility or incompatibility with the adhesive. In addition, drug crystallization and poor adhesion can reduce the overall delivery performance of the patch. [16,17]

4.1.2. Matrix-Type Patches.

Matrix-type patches contain a drug that is dissolved or dispersed within a solid or semisolid polymer matrix. This drug-containing matrix is attached to a backing layer, while an adhesive layer or adhesive border keeps the patch in contact with the skin. The matrix holds the drug and plays an important role in controlling its release.

After the patch is applied, drug molecules diffuse through the polymer matrix toward the skin along a concentration gradient. The release rate is influenced by factors such as polymer composition, matrix thickness, drug solubility, polymer swelling, and drug diffusivity. Once released from the matrix, the drug must enter and permeate through the skin.

One limitation of matrix-type patches is that drug release may decrease over time as the amount of readily available drug falls. The release pattern may also be affected by matrix thickness, interactions between the drug and polymer, and uneven drug distribution. In some cases, the formulation may not have sufficient flexibility or mechanical strength. [16,17]

4.1.3. Reservoir-Type Patches.

Reservoir-type patches contain a separate drug reservoir, in which the medicine may be present as a solution, suspension, or gel. The reservoir is placed between an impermeable backing layer and a rate-controlling membrane. An adhesive layer keeps the patch in contact with the skin, while a release liner protects the adhesive before use.

After application, the drug moves from the reservoir through the rate-controlling membrane and then into the skin. If the reservoir maintains a suitable drug concentration and the membrane effectively controls transport, the patch may provide a relatively constant release rate over a defined period. However, actual delivery is also affected by membrane properties, drug depletion, and skin permeability.

Compared with matrix or drug-in-adhesive patches, reservoir systems have a more complex design and manufacturing process. Problems such as reservoir leakage, membrane damage, and formulation instability can affect their performance. Leakage is particularly concerning because it may expose the user to an unintended amount of drug. [16,17]

4.1.4. Membrane-Controlled Patches.

In membrane-controlled patches, the drug reservoir is separated from the skin by a polymeric membrane that controls the rate of drug release. These patches generally consist of a backing layer, drug reservoir, rate-controlling membrane, adhesive layer, and release liner. Because reservoir-type patches commonly use this design, the terms "reservoir-type" and "membrane-controlled" are closely related rather than completely separate categories.

The membrane regulates the movement of the drug from the reservoir toward the skin. Its release rate depends on factors such as membrane permeability, thickness, surface area, and the concentration gradient of the drug across the membrane. Under suitable conditions, this design can provide a more consistent and predictable release profile.

However, membrane-controlled systems depend on the membrane remaining intact and compatible with the drug formulation. Manufacturing defects, membrane damage, or changes in drug concentration can alter the release rate and affect patch performance. [16,22]



Fig 2- Types of Transdermal Patches

Polymers Used in Transdermal Patch Formulation. [16,17]

Polymers are essential in transdermal drug delivery systems because they form the basic structure of the patch and influence drug loading, release, adhesion, flexibility, and stability. Depending on the formulation, they may function as matrix-forming materials, pressure-sensitive adhesives, gelling agents in drug reservoirs, or rate-controlling membranes. Choosing a suitable polymer depends on its physicochemical properties, compatibility with the drug, mechanical strength, biocompatibility, and ability to produce the desired drug-release profile. [16,17]

Table 1- Polymer used in Transdermal Patches

POLYMER	MAIN ROLE	IMPORTANT PROPERTIES	POTENTIAL LIMITATIONS
HPMC	Matrix and film-forming agent	Hydrophilic; swelling and release modifying properties	Excessive swelling may affect formulation performance
PVP	Film- forming agent, Polymer blend component	Hydrophilic; can influence drug solubility	Moisture sensitivity
Ethyl cellulose	Matrix or release modifying film	Hydrophobic; can retard diffusion	May reduce drug release excessively
Eudragit	Film and matrix- forming polymer	Properties vary by polymer grade	Requires grade-specific selection
PVA	Film forming agent	Hydrophilic; forms polymeric films	Swelling may influence release and strength
Polyacrylates	Pressure- sensitive adhesive	Flexible; suitable for selected skin-contact applications	Drug compatibility and skin tolerance must be evaluated
Silicone Polymers	Pressure sensitive adhesive	Flexible; suitable for selected skin-contact applications	Drug compatibility varies
EVA	Rate controlling membrane	Permeability can be tailored	Performance depends on membrane properties
Polyurethane	Film or membrane material	Adjustable mechanical and transport properties	Properties vary with grade and composition
Chitosan	Experimental film forming polymer	Biopolymer; useful in selected drug delivery formulations	Solubility and mechanical properties may require modification

Importance of Polymer Selection for Migraine Patches:

For a polymer-based transdermal patch used in migraine management, the choice of polymer should match the physicochemical properties of the selected anti-migraine drug and the intended delivery profile. The formulation should provide adequate drug loading, consistent release, reliable skin adhesion, mechanical stability, and good skin tolerability.

Because the stratum corneum is a major barrier to absorption, the polymer matrix alone may not provide enough drug permeation for every medicine. Permeation enhancers or specialized delivery technologies may therefore need to be considered. The final formulation should be evaluated through tests such as drug-content uniformity, thickness, folding endurance, moisture content, adhesion, in-vitro drug release, and ex-vivo skin-permeation studies. [16,22]

4.2. Components of a Polymer-Based Transdermal Patch:

A polymer-based transdermal patch is designed to deliver an active pharmaceutical ingredient (API) through the skin and into the bloodstream. Its formulation includes several components, such as the drug, polymer matrix, plasticizer, skin permeation enhancer, pressure-sensitive adhesive, backing membrane, and release liner. Each component has a specific role in maintaining patch stability, controlling drug release, improving skin permeation, and ensuring adequate adhesion. Careful selection of these materials and confirmation of their compatibility are essential for developing an effective and safe transdermal formulation. [16,24]

4.2.1. Active Pharmaceutical Ingredient (API).

The active pharmaceutical ingredient (API) is the medicine responsible for producing the intended therapeutic effect. In a transdermal patch for migraine management, the selected drug should have suitable properties for skin permeation, as well as sufficient potency and stability. Depending on the patch design, the drug may be dissolved or dispersed in the polymer matrix, incorporated into the adhesive, or placed in a separate reservoir. Factors such as drug loading, solubility, molecular size, and compatibility with excipients can influence drug release and its subsequent movement through the skin. [16,24]

4.2.2. Polymer Matrix.

The polymer matrix is the main drug-holding and film-forming component in matrix-type patches. It gives the patch its structure and influences the rate of drug release by controlling diffusion through the polymer network. Commonly studied polymers include hydroxypropyl methylcellulose (HPMC), ethyl cellulose (EC), polyvinylpyrrolidone (PVP), and suitable methacrylate-based polymers. The most appropriate polymer is selected according to its compatibility with the drug, mechanical properties, film-forming ability, and capacity to provide the desired release profile. [16]

4.2.3. Plasticizer.

Plasticizers are added to polymer formulations to make the prepared film more flexible, less brittle, and easier to handle. They reduce the interactions between polymer chains, allowing the chains to move more freely. Common examples include polyethylene glycol (PEG), propylene glycol, and triethyl citrate, depending on the polymer and formulation. The type and concentration of plasticizer should be carefully optimized, since excessive amounts can weaken the film, make it too sticky, or change the drug-release pattern. [16,24]

4.2.4. Skin Permeation Enhancer.

Skin permeation enhancers are added to transdermal formulations to help drugs pass through the stratum corneum, which is the main barrier to skin penetration. They may work by altering the arrangement of skin lipids, improving the drug's ability to enter the skin, or increasing drug solubility in the formulation. Common examples include ethanol, propylene glycol, oleic acid, and selected surfactants. Their concentration must be carefully optimized to improve drug permeation while minimizing skin irritation and damage to the skin barrier. [24]

4.2.5. Pressure-Sensitive Adhesive (PSA).

A pressure-sensitive adhesive allows the patch to stick to the skin with gentle pressure and remain in place throughout the intended period of use. Reliable adhesion is important for consistent drug delivery, since lifting or detachment can reduce the area of contact with the skin. Common adhesive materials include polyacrylate-based, silicone-based, and polyisobutylene-based adhesives. The adhesive should be compatible with the drug and other excipients while providing suitable adhesion, cohesion, and skin tolerability. In drug-in-adhesive patches, it also serves as the drug-containing matrix. [16,24]

4.2.6. Backing Membrane.

The backing membrane, or backing layer, is the outer protective layer of a transdermal patch. It provides mechanical support and protects the formulation from moisture, contamination, and other environmental factors. It can also help prevent drug loss from the outer surface, directing drug delivery toward the skin. Common materials include polyester, polyethylene, and other suitable polymer films. The backing material should be flexible and compatible with the formulation to prevent cracking, leakage, or unwanted interactions during storage and use. [16,24]

4.2.7. Release Liner.

The release liner is a protective layer that covers the adhesive or drug-contact surface of a patch during storage. It is removed immediately before the patch is applied. Its main purpose is to prevent contamination, avoid premature contact with the adhesive, and preserve the quality of the patch until use. Release liners are commonly made from paper or polymer films coated with release agents such as silicone. The material should be chemically inert and easy to remove without pulling away the drug formulation or damaging the adhesive layer. [16,24]

4.3. Sumatriptan As A Drug for Transdermal Migraine Delivery.

Sumatriptan is a selective serotonin 5-HT$_1$B/$_1$D receptor agonist used for the acute treatment of migraine. Transdermal delivery has been explored because nausea, vomiting, and delayed gastric emptying during migraine attacks can make oral treatment less reliable. However, delivering sumatriptan through intact skin using a conventional passive patch is challenging. Its physicochemical properties and dose requirements limit the amount of drug that can pass through a practical patch area. As a result, iontophoresis, which uses a small electrical current to enhance drug transport across the skin, has been investigated as an alternative approach

The sumatriptan iontophoretic transdermal system has been studied for the acute treatment of migraine and is an important example of how specialized delivery technology may help overcome the limitations of passive skin permeation. Microneedle-assisted systems have also been investigated to improve the transport of anti-migraine drugs across the skin. However, choosing a drug and delivery method should be supported by evidence on drug flux, dose delivery, safety, and reliable clinical performance.

Sumatriptan acts mainly as an agonist at serotonin 5-HT$_1$B and 5-HT$_1$D receptors. Activating these receptors contributes to cranial vasoconstriction and reduces the release of trigeminal neuropeptides, including calcitonin gene-related peptide (CGRP). Together, these effects help reduce the transmission of migraine-related pain signals. When sumatriptan is delivered through the skin, it must first cross the skin barrier and enter systemic circulation before producing its therapeutic effect. The success of a transdermal formulation therefore depends on both the pharmacological activity of sumatriptan and the ability of the formulation to deliver an adequate dose through the skin. [1,2,16]

4.4. Rationale for Transdermal Delivery of Sumatriptan.

The main purpose of transdermal sumatriptan delivery is to provide a non-oral treatment option for acute migraine. Nausea and vomiting can make tablets difficult to swallow and may interfere with the absorption of oral medication. A transdermal system avoids the gastrointestinal tract as the first stage of drug delivery. However, the stratum corneum, the outermost layer of the skin, creates a major barrier to sumatriptan permeation. As a result, conventional passive patches may not deliver a sufficient dose efficiently, making specialized approaches such as iontophoresis and microneedle-assisted delivery important areas of research. [2]

4.5. Mechanism of Drug Release from A Polymer Matrix:

Drug release from a polymer-based transdermal patch begins when the active pharmaceutical ingredient (API) moves from the polymer matrix to the surface of the skin. The drug then permeates through the skin and is absorbed into the bloodstream. This process is mainly influenced by drug diffusion, interactions between the drug and polymer, partitioning between the formulation and the skin, and the permeability of the stratum corneum. The delivery rate also depends on the drug's physicochemical properties, polymer composition, matrix thickness, drug concentration, and individual skin characteristics. [25]

4.5.1. Drug Dispersion within the Polymer Matrix.

In a matrix-type transdermal patch, the active pharmaceutical ingredient is dissolved or evenly dispersed throughout a polymer network. Polymers such as hydroxypropyl methylcellulose (HPMC), ethyl cellulose, and other film-forming materials act as drug reservoirs while providing the patch with structural strength. Depending on its solubility and compatibility with the polymer, the drug may be present in a dissolved form or as solid particles. Even distribution of the drug is important because it supports consistent release and prevents differences in the amount delivered from different areas of the patch. Interactions between the drug and polymer, as well as the properties of the polymer itself, influence how easily the drug can move and become available for diffusion. [22,25]

4.5.2. Drug Diffusion from the Polymer Matrix.

After the patch is applied, drug molecules move from areas of higher concentration within the polymer matrix toward areas of lower concentration near the skin surface. This movement mainly occurs by diffusion along a concentration gradient. The diffusion rate depends on the drug's molecular size, its solubility in the polymer, its diffusivity within the matrix, and the thickness and structure of the polymer film. In some formulations, swelling of the polymer can also affect how easily the drug moves. As the drug is released over time, its concentration in the matrix gradually decreases, which may slow the release rate. [22,25]

4.5.3. Partitioning of the Drug at the Skin Surface.

Once the drug reaches the boundary between the patch and the skin, it must move from the formulation into the stratum corneum, the outermost layer of the skin. This process, known as partitioning, describes how the drug distributes between two contacting phases: the polymer formulation and the skin. Effective partitioning depends on factors such as the drug's lipophilicity, solubility, ionization state, and affinity for both the polymer and skin lipids. If the drug binds too strongly to the polymer, it may remain in the matrix and be released slowly. In contrast, suitable drug–skin partitioning can support its transfer into the skin. The polymer must therefore retain the drug during storage while still allowing its release after the patch is applied. [22,25]

4.5.4. Permeation through the Stratum Corneum.

After entering the skin, the drug must cross the stratum corneum, the outermost layer of the epidermis and the main barrier to transdermal delivery. Drug molecules usually pass through the skin by the intercellular route, moving through the lipid-rich spaces between corneocytes, or by the transcellular route, crossing the corneocytes and their surrounding membranes. A third, generally more limited route involves skin appendages, such as hair follicles and sweat ducts.

The rate of skin permeation depends on factors such as molecular size, lipid and water solubility, skin condition, and the use of permeation enhancers. Enhancers including ethanol, propylene glycol, and selected fatty acids may improve drug transport by changing drug solubility, supporting partitioning into the skin, or altering the organization of skin lipids. [15,22]

4.5.5. Transport into the Systemic Circulation.

After crossing the stratum corneum, the drug moves through the viable epidermis and into the dermis, where a network of small blood vessels supports its absorption into systemic circulation. Once it reaches the dermal blood supply, the drug can be distributed throughout the body and produce its pharmacological effect. The amount absorbed depends on the drug's permeability, the concentration gradient across the skin, the effective area of the patch, and how long it remains applied. Successful systemic delivery therefore requires both adequate drug release from the polymer matrix and sufficient permeation through the skin. [15,22]

5. SKIN PERMEATION ENHANCEMENT:

5.1. Chemical Permeation Enhancers.

Chemical permeation enhancers (CPEs) are substances added to transdermal drug delivery systems to help drugs move across the skin more effectively. The stratum corneum, made up of corneocytes within a lipid-rich matrix, is the main barrier to skin permeation. Chemical enhancers temporarily alter this barrier, increasing skin permeability and supporting drug diffusion. They may also improve the drug's solubility within the formulation or help it partition from the polymer matrix into the skin. An enhancer's effectiveness depends on its concentration, the physicochemical properties of the drug, and its interactions with both the polymer matrix and the skin. [15,26]

5.1.1. Mechanism of Action of Chemical Permeation Enhancers:

Chemical permeation enhancers can improve drug transport across the skin through several mechanisms:

- **5.1.1.1 Disrupting stratum corneum lipids.** Some enhancers interact with the intercellular lipid layers and change their organization, reducing resistance to drug diffusion. Examples include oleic acid, selected terpenes, and certain alcohols.
- **5.1.1.2. Interacting with skin proteins.** Some enhancers may interact with keratin in the corneocytes, causing changes in protein structure that can increase drug diffusivity through the skin.
- **5.1.1.3. Improving drug partitioning.** Certain enhancers help the drug move from the formulation into the stratum corneum, supporting its entry into the skin.
- **5.1.1.4. Increasing drug solubility and diffusion.** Some enhancers act as solvents or co-solvents, improving drug solubility in the formulation and facilitating its movement toward and through the skin. [15,19]

Types of Chemical Permeation Enhancers:

Alcohols.

Alcohols such as ethanol and isopropyl alcohol are used in some transdermal formulations as solvents and skin-permeation enhancers. They can improve drug solubility and alter the organization of lipids in the stratum corneum, which may support drug transport across the skin. However, high concentrations or repeated exposure can cause dryness and irritation. Their suitability depends on the drug's solubility, compatibility with the polymer, and the intended formulation. [15,26]

Glycols.

Propylene glycol and polyethylene glycol (PEG) are used for different purposes in pharmaceutical formulations. Depending on the formulation, propylene glycol can act as a solvent, humectant, or chemical permeation enhancer. It may improve drug solubility and help the drug partition into the skin. PEG is commonly used as a solvent or excipient, but it should not be assumed to enhance skin permeation to the same extent as propylene glycol. High concentrations of certain glycols may affect skin tolerability or alter the physical properties of the patch. [15,26]

Fatty Acids.

Fatty acids, especially oleic acid, are investigated as chemical permeation enhancers because they can interact with the lipid domains between cells in the stratum corneum. This interaction may disrupt lipid packing and allow drugs to diffuse through the skin more easily. Their effectiveness depends on the concentration used, the properties of the drug, and the overall formulation. However, excessive amounts may cause irritation or weaken the skin barrier.

Surfactants.

are surface-active agents that can improve wetting and drug solubilization. Some may also interact with skin lipids and proteins, increasing skin permeability. Their effect varies according to the type and concentration of surfactant, as well as its interaction with other formulation ingredients. At high concentrations, certain surfactants may irritate the skin or damage its barrier function, so they must be selected carefully. [15,26]

Terpenes.

Terpenes are naturally occurring compounds found in essential oils. Examples studied for transdermal delivery include menthol, limonene, and cineole. Depending on their chemical structure, they may interact with lipids in the stratum corneum, alter lipid organization, or improve the drug's ability to partition into the skin. Although terpenes are promising permeation enhancers, their effectiveness and skin tolerability can vary. Their natural origin does not automatically mean they are safe for every formulation or user. [15,26]

Chemical Permeation Enhancers Relevant to Polymer-Based Migraine Patches:

In polymer-based patches for migraine treatment, chemical permeation enhancers may be explored to improve drug transport across the stratum corneum. Ethanol, propylene glycol, and selected fatty acids are possible formulation ingredients, but their suitability must be evaluated for the specific drug and polymer system. An enhancer that improves drug release from a polymer matrix does not necessarily improve drug permeation through the skin, so these processes should be assessed separately.

For sumatriptan, which is difficult to deliver through intact skin using passive methods, formulation development must demonstrate sufficient drug flux while preserving skin integrity and ensuring acceptable tolerability. Research on migraine-specific transdermal delivery has also investigated physical approaches, including iontophoresis and microneedles. [19,1]

5.2 Physical Permeation Enhancers.

Physical permeation-enhancement techniques are used to improve drug transport across the stratum corneum (SC), the outermost layer of the skin and the main barrier to transdermal delivery. These methods use electrical energy, mechanical force, ultrasound, or microscopic structures to increase skin permeability and support drug absorption. Major approaches include iontophoresis, microneedles, electroporation, and sonophoresis. Their potential use in migraine management is particularly relevant because drugs such as sumatriptan can be difficult to deliver through conventional passive patches. [13,27]

Iontophoresis.

Iontophoresis is a physical enhancement method that uses a low-intensity electrical current to help drugs move across the skin. It supports the transport of charged drug molecules through electromigration and electro-osmosis. By adjusting the current intensity and duration of application, the rate of drug delivery can be controlled.

This approach has been investigated for acute migraine treatment using a sumatriptan iontophoretic patch. The electrical current helps deliver sumatriptan through the skin, providing an alternative to oral medication. However, a previously marketed sumatriptan iontophoretic patch was withdrawn after reports of skin burns and scarring. This highlights the importance of careful device design and thorough safety evaluation when developing iontophoretic delivery systems. [27]

Microneedles.

Microneedles are tiny needle-like projections that create small pathways through the stratum corneum. These pathways can help drugs enter the skin while avoiding the deeper tissue penetration associated with conventional hypodermic needles. Depending on their design, microneedles may be solid, coated, hollow, or dissolving. Dissolving microneedles are commonly made from water-soluble or biodegradable polymers that release the incorporated drug after they are inserted into the skin.

Microneedle-based systems have been studied for the transdermal delivery of sumatriptan succinate. Experimental studies using dissolving polyvinylpyrrolidone (PVP)-based microneedles have shown potential for improving sumatriptan transport across the skin. These findings support further investigation of microneedle-assisted migraine treatment; however, laboratory skin-permeation results alone do not demonstrate clinical effectiveness. [27]

Electroporation.

Electroporation uses short, high-voltage electrical pulses to temporarily increase skin permeability. These pulses cause brief changes in the barrier properties of the stratum corneum, allowing drugs to move through the skin more easily. The extent of this effect depends on factors such as pulse voltage, duration, frequency, and the properties of the drug formulation.

This technique may be useful for drugs that cannot penetrate the skin adequately through conventional polymer-based patches. However, excessive electrical exposure can cause irritation, discomfort, or tissue damage. The electrical settings must therefore be carefully optimized, and skin integrity should be assessed during formulation development. Further research is needed before electroporation can be established for migraine-specific transdermal patches. [13,27]

Sonophoresis.

Sonophoresis is a technique that uses ultrasound waves to improve drug permeation across the skin. Its main mechanism, particularly with low-frequency ultrasound, is acoustic cavitation. During this process, microscopic bubbles form and collapse, temporarily disturbing the skin barrier and increasing its permeability. Mechanical effects caused by ultrasound and, in some cases, local heating may also contribute to improved drug transport.

Sonophoresis may be useful for delivering compounds that do not pass easily through intact skin. In migraine management, it could be investigated as an additional method for polymer-based patches containing suitable anti-migraine drugs. However, its effectiveness depends on the ultrasound frequency, intensity, duration of exposure, drug properties, and formulation design. Excessive ultrasound exposure may damage skin tissue, so careful safety and permeation studies are needed before clinical use. [27,28,29]

5.3 Factors affecting Skin Permeation:

5.3.1. Physicochemical Properties of the Drug;

Molecular weight: Molecular weight: Drugs with lower molecular weights generally pass through the skin more readily than larger molecules. Therefore, molecular weight is an important factor when selecting a drug for transdermal delivery.

Lipophilicity. A drug needs an appropriate balance between lipid and water solubility. It must cross the lipid-rich stratum corneum and then move through the more aqueous environment of deeper skin tissues.

Drug concentration: Increasing drug concentration may strengthen the concentration gradient and improve permeation, provided the drug remains sufficiently soluble in the formulation.

Ionization. The degree of drug ionization affects its solubility and ability to partition into the skin. This depends on the drug's pKa, the pH of the formulation, and conditions at the skin surface. [15,16]

5.3.2. Physiological Factors of the Skin:

Skin thickness. Differences in skin thickness and barrier properties can affect how quickly a drug penetrates the skin.

Skin hydration. Hydrated skin may allow greater drug permeation because hydration can change the structure and barrier function of the stratum corneum.

Skin integrity. Damaged, inflamed, or irritated skin can have altered permeability, making drug absorption less predictable.

Skin temperature. Temperature may influence drug diffusion and the behavior of skin lipids.

Skin site and age. Permeability can vary according to the anatomical site of application, age, and individual differences in skin characteristics. [15,16]

5.3.2. Formulation-Related Factors:

Polymer type and concentration. The polymer controls drug incorporation, diffusion, and release from the patch. Strong drug–polymer interactions or a dense polymer matrix can slow drug release.

Permeation enhancers. Substances such as propylene glycol, oleic acid, and menthol may improve drug penetration by modifying the skin barrier or enhancing drug partitioning into the skin.

Plasticizers. Depending on their role in the formulation, plasticizers such as polyethylene glycol or propylene glycol can affect polymer flexibility and drug diffusion.

Patch thickness and drug loading. These factors affect the amount of drug available for release and the distance the drug must diffuse through the formulation.

Adhesion and contact time. Good contact between the patch and skin supports consistent drug delivery. Poor adhesion can reduce the effective contact area and lead to variable drug absorption. [15,16]

6. FORMULATION DEVELOPMENT AND EVALUATION OF POLYMER-BASED PATCHES:

6.1.Patch Preparation Techniques.

Preparing polymer-based transdermal patches involves incorporating the drug into a suitable polymer system to produce a uniform film with controlled drug-release properties. The method used can affect the patch's thickness, flexibility, drug distribution, mechanical strength, and release behavior. Common development approaches include solvent casting, film casting followed by drying, matrix formation, and drug–polymer mixing followed by film formation. [22,30]

6.1.1. Solvent Casting Method:

Solvent casting is a commonly used method for preparing polymer-based transdermal patches. In this method, the drug and selected polymer are dissolved or dispersed in a suitable solvent system. Plasticizers and permeation enhancers may also be added to improve film flexibility and drug permeation. The mixture is then poured into a mould and dried under controlled conditions. As the solvent evaporates, a drug-loaded polymer film is formed. After drying, the film is removed from the mould and cut into patches of the required size.

6.1.1.1. Advantages. Solvent casting is relatively simple, economical, and well suited to laboratory-scale formulation development. The polymer concentration and drug loading can be varied to study their effects on drug release.

6.1.1.2. Limitations. Residual solvent, uneven drying, drug crystallization, air bubbles, and non-uniform film thickness can affect the quality and performance of the final patch. [22,30]



Fig 3- Formulation of transdermal patches by Solvent Casting Method

6.1.2. Film Casting and Drying:

Film casting and drying involve spreading a drug-containing polymer solution or dispersion over a flat surface to form a film with controlled thickness. The prepared mixture is poured onto a level glass plate, Petri dish, or another suitable casting surface, and the solvent is allowed to evaporate under controlled temperature and environmental conditions. Once fully dry, the film is carefully removed and evaluated for uniformity, flexibility, and mechanical strength.

Drying conditions are important because rapid or uneven solvent evaporation can create defects, while insufficient drying may leave residual solvent in the film. Adding a suitable plasticizer can improve flexibility and reduce brittleness. Film thickness and drying conditions should therefore be optimized to achieve consistent drug-release characteristics. [30]

6.1.3. Matrix Formation:

Matrix formation is a formulation approach in which the drug is evenly dissolved or dispersed throughout a polymer network. The polymer matrix acts as a carrier and controls drug release through diffusion, dissolution, or a combination of both mechanisms. Hydrophilic or hydrophobic polymers may be selected based on the desired release profile and their compatibility with the drug. [2,3]

In a typical matrix-type patch, the drug and polymer are mixed to create a uniform drug-containing phase. This mixture is then cast or otherwise processed into a film and allowed to dry or solidify. Depending on the patch design, the resulting drug-loaded matrix may be combined with a backing layer, pressure-sensitive adhesive, and release liner.

6.1.3.1. Advantages: Matrix systems can provide controlled drug release, have a relatively simple structure, and carry a lower risk of leakage than liquid reservoir systems.

6.1.3.2. Limitations: Drug release may vary according to polymer composition, drug distribution, matrix thickness, and drug–polymer interactions. Uneven drug distribution can result in inconsistent dosing. [22]

6.1.4. Drug–Polymer Mixing and Film Formation:

Drug–polymer mixing is a key step in preparing matrix-type transdermal patches. Depending on the physicochemical properties of the drug and polymer, the drug may be incorporated by dissolution, dispersion, or blending. A suitable solvent or processing method is chosen to produce a homogeneous mixture, and plasticizers or permeation enhancers may be added when needed.

The mixture is then cast into a mould or onto a flat surface and dried under controlled conditions to form a film. The resulting patch can be evaluated for drug-content uniformity, thickness, folding endurance, tensile properties, moisture content, and in-vitro drug release. Compatibility studies, such as Fourier-transform infrared spectroscopy (FTIR), may also be used to assess possible interactions between the drug and polymer.

Uniform drug distribution and appropriate polymer selection are essential for achieving reproducible drug release and consistent formulation performance. [22,30]

Evaluation Parameters. [16,15,22]

Table 2-Evaluation Parameters

Parameter	Method or Instrument	Purpose
Appearance	Visual Inspection	Detects cracks, bubbles and surface defects
Thickness Uniformity	Digital Micrometer	Determines consistency of film thickness
Weight variation	Analytical balance	Assesses variation in patch weight
Drug content uniformity	UV-visible spectrophotometry or HPLC	Determines drug content and distribution
Folding endurance	Repeated folding test	Evaluates flexibility and resistance to folding
Tensile strength	Tensile testing instrument	Measures resistance to breaking
Percentage elongation	Tensile testing instrument	Measures stretching before breakage
Moisture Content	Controlled drying and weighing	Determines the amount of moisture present
Moisture Uptake	Controlled humidity exposure	Assesses moisture absorption
Surface pH	Calibrated Ph meter	Helps assess potential skin compatibility

7. SAFETY CONSIDERATIONS:

Safety is a key consideration when developing polymer-based transdermal drug delivery systems for migraine management. Although patches can provide controlled drug delivery and avoid gastrointestinal absorption, their safety depends on the drug, polymer, adhesive, permeation enhancers, patch design, and duration of contact with the skin. Potential concerns include skin

irritation, allergic contact dermatitis, excessive drug permeation, formulation instability, and device-related adverse effects. Safety assessment should therefore be included throughout formulation development and clinical evaluation. [31,32]

7.1.Skin Irritation and Allergic Reactions.

Skin irritation is one of the most common safety concerns with transdermal patches. It may cause redness, itching, burning, swelling, or discomfort at the application site. Allergic contact dermatitis can also occur in response to certain polymers, pressure-sensitive adhesives, drugs, or other formulation ingredients. Chemical permeation enhancers may further disrupt the skin barrier and increase irritation if used at unsuitable concentrations.

To reduce these risks, formulation components should be chosen for their compatibility and skin tolerability. Appropriate validated studies of skin irritation and sensitization should be completed before a formulation proceeds to clinical testing. [31,32]

7.2. Safety of Polymers and Excipients.

Plasticizers, adhesives, solvents, and permeation enhancers must be assessed for their suitability in transdermal use. Incompatible excipients can affect drug stability, film integrity, adhesion, and skin tolerability. Residual solvents left behind after incomplete drying may also create quality and safety concerns. Formulation development should therefore include drug–excipient compatibility studies, residual-solvent testing, and stability assessment. Selecting biocompatible materials is particularly important for patches designed to remain on the skin for extended periods. [31,33]

7.3. Dose Control and Systemic Adverse Effects.

Transdermal patches must deliver the intended drug dose at a suitable rate. Excessive drug release or permeation may result in unnecessarily high systemic exposure, whereas inadequate delivery may reduce therapeutic effectiveness. Drug crystallization, changes in polymer properties, poor adhesion, and formulation defects may contribute to variable drug delivery. For migraine management, these considerations are important when developing patches containing sumatriptan or other potential antimigraine agents. The formulation must provide reproducible drug delivery while maintaining the safety profile of the active drug. Drug-release studies, skin-permeation experiments, and appropriate pharmacokinetic and clinical evaluations are necessary to establish performance and safety. [31,32]

7.4.Migraine-Specific Safety Considerations.

The sumatriptan iontophoretic transdermal system marketed as Security illustrates the importance of thorough safety evaluation. The product was withdrawn after reports of burns and scarring associated with its use. A review by Loder and colleagues raised concerns about adverse-event reporting, product information, and how safety was assessed during product development and after marketing.

This experience shows that effective drug delivery alone is not enough to establish the overall safety of a transdermal system. For migraine patches, both drug-related adverse effects and skin reactions caused by the formulation or device must be considered. Security should be viewed as a safety case study, rather than as evidence that all iontophoretic patches are unsafe. [28]

7.5. Stability, Adhesion, and Manufacturing Quality.

Maintaining the physical and chemical stability of a transdermal patch is important to ensure that it remains safe and effective throughout storage and use. Factors such as temperature, humidity, and interactions between the drug, polymer, adhesive, and other ingredients can affect the stability of the medicine, flexibility of the film, patch adhesion, and drug-release pattern. Product quality may also be affected by manufacturing problems, including uneven drug distribution, variable patch thickness, poor adhesion, or residual solvent remaining after preparation. For these reasons, stability testing, quality-control checks, and careful manufacturing procedures are needed before a formulation can move forward in development. [31,33]

8. CONCLUSION:

Transdermal drug delivery systems (TDDS) offer a promising alternative approach for migraine treatment. During an acute migraine attack, nausea and vomiting can make it difficult to take oral medication and may also interfere with drug absorption. By delivering medicine through the skin, transdermal systems can avoid the gastrointestinal tract and first-pass metabolism in the liver. They may also provide controlled drug release and offer a more convenient treatment option for some patients.

Developing polymer-based transdermal patches requires careful selection of the active pharmaceutical ingredient, polymer matrix, plasticizers, permeation enhancers, adhesives, and other formulation components. Methods such as solvent casting and film formation can be used to prepare drug-loaded polymer films with specific physical properties and release patterns. Evaluating thickness uniformity, drug content, mechanical properties, drug–polymer compatibility, and stability is essential for confirming formulation quality. However, the effectiveness of these systems still depends greatly on the physicochemical properties of the drug and the barrier function of the stratum corneum.[15,16]

Chemical permeation enhancers and physical methods, such as iontophoresis, microneedles, electroporation, and sonophoresis, may help improve drug transport across the skin. Among anti-migraine medicines, sumatriptan has been studied using iontophoretic delivery and experimental microneedle-based systems. However, the withdrawal of a previously marketed sumatriptan iontophoretic patch after reports of burns and scarring highlights the need for thorough safety evaluation. Improving skin permeation must therefore be balanced with good skin tolerability, consistent drug delivery, and device safety.

In conclusion, polymer-based transdermal patches may offer a useful option for migraine management, but further research is needed before they can be widely used. Future work should focus on identifying suitable drugs, optimizing polymer composition, improving skin permeation, and achieving consistent drug-release profiles. Studies should include validated in-vitro release and ex-vivo permeation tests, stability assessments, skin-irritation studies, pharmacokinetic evaluation, and well-designed clinical trials. Ultimately, a successful migraine patch must do more than improve drug transport through the skin; it must also provide effective treatment, acceptable safety, and a convenient experience for patients.

REFERENCE:

1. Sueiro AC, dos Santos EM, Tundisi LL, et al. Transdermal delivery systems for migraine treatment: A gap to explore. Journal of Drug Delivery Science and Technology. 2022;77: 103919. doi:10.1016/j. jddst.2022.103919. https://doi.org/10.1016/j.jddst.2022.103919

2. Ita K, Ukaoma M. Progress in the transdermal delivery of antimigraine drugs. Journal of Drug Delivery Science and Technology. 2022;68 :103064. doi:10.1016/j. jddst.2021.103064. ScienceDirect

3. Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment

Lu W, Zhang Y. Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment. MedComm. 2026;7(9):e70933. doi:10.1002/mco2.70933. https://doi.org/10.1002/mco2.70933

4. Noseda R, Burstein R. Migraine pathophysiology: Anatomy of the trigemino vascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(Suppl 1):S44–S53. doi:10.1016/j.pain.2013.07.021.

5. Pathophysiology of migraine

Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annual Review of Physiology. 2013;75:365–391. doi:10.1146/annurev-physiol-030212-183717. https://doi.org/10.1146/annurev-physiol-030212-183717

6. Cortical spreading depression and migraine

Charles AC, Baca SM. Cortical spreading depression and migraine. Nature Reviews Neurology. 2013;9:637–644. https://doi.org/10.1038/nrneurol.2013.192.

7. Becker WJ. Acute migraine treatment. Continuum (Minneap Minn). 2015;21(4 Headache):953–972. https://doi.org/10.1212/CON.0000000000000192

8. Novel optimization of multi-mechanistic approaches for the acute treatment of a migraine attack: A review

Silberstein SD, et al. Novel optimization of multi-mechanistic approaches for the acute treatment of a migraine attack: A review. Headache. 2026. https://pubmed.ncbi.nlm.nih.gov/41781342/

9. Diagnosis and management of migraine in ten steps

Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nature Reviews Neurology. 2021;17:501–514. https://doi.org/10.1038/s41582-021-00509-5

10. Approach to headache disorders and the management of migraine

Zhao YJ, et al. Approach to headache disorders and the management of migraine: Consensus guidelines from the Headache Society of Singapore, first edition (2023). Singapore Medical Journal. https://pmc.ncbi.nlm.nih.gov/articles/PMC13405573/

11. Sueiro AC, et al. Transdermal delivery systems for migraine treatment: A gap to explore. Journal of Drug Delivery Science and Technology. 2022;77: 103919. doi:10.1016/ j. jddst.2022.103919.

12. Exploring Nose to Brain Nano Delivery for Effective Management of Migraine

Tanna V, Sawarkar SP, Ravikumar P. Exploring Nose to Brain Nano Delivery for Effective Management of Migraine. Current Drug Delivery. 2023;20(2):144–157. https://pubmed.ncbi.nlm.nih.gov/35366772/

13. Sumatriptan transdermal iontophoretic patch

Vikelis M, Mitsikostas DD, Rapoport AM. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): Review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatric Disease and Treatment. 2012;8:429–434. https://pmc.ncbi.nlm.nih.gov/articles/PMC3460671/

14. Overcoming skin barriers through advanced transdermal drug delivery approaches. Journal of Controlled Release. 2022; 351: 361–380. https://doi.org/10.1016/j.jconrel.2022.09.025

15. Ramadon D, McCrudden MTC, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: Current trends and applications. Drug Delivery and Translational Research. 2022; 12: 758–791. https://doi.org/10.1007/s13346-021-00909-6

16. Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharmaceutica. 2019;69(2):197–215. doi:10.2478/acph-2019-0016.

17. Recent Advancement of Medical Patch for Transdermal Drug Delivery

Wong WF, Ang KP, Sethi G, Looi CY. Recent Advancement of Medical Patch for Transdermal Drug Delivery. Medicina. 2023;59(4):778. https://doi.org/10.3390/medicina59040778

18. How physical techniques improve the transdermal permeation of therapeutics: A review

Gao Y, Du L, Li Q, et al. How physical techniques improve the transdermal permeation of therapeutics: A review. Medicine. 2022;101(26):e29314. https://pmc.ncbi.nlm.nih.gov/articles/PMC9239599/

19. Lee et al. Advancements in Skin-Mediated Drug Delivery: Mechanisms, Techniques, and Applications. Advanced Healthcare Materials. 2024;13(7):2302375. doi:10.1002/adhm.202302375.

20. Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems

Alkilani AZ, Nasereddin J, Hamed R, et al. Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems. Pharmaceutics. 2022;14(6):1152. https://doi.org/10.3390/pharmaceutics14061152

21. Transdermal Patches: The Emerging Mode of Drug Delivery System in Psychiatry

Isaac M, Holvey C. Transdermal patches: The emerging mode of drug delivery system in psychiatry. Therapeutic Advances in Psychopharmacology. 2012;2(6):255–263. https://doi.org/10.1177/2045125312458311

22. The Design Features, Quality by Design Approach, Characterization, Therapeutic Applications, and Clinical Considerations of Transdermal Drug Delivery Systems—A Comprehensive Review

Sivadasan D, Madkhali OA. The Design Features, Quality by Design Approach, Characterization, Therapeutic Applications, and Clinical Considerations of Transdermal Drug Delivery Systems—A Comprehensive Review. Pharmaceuticals. 2024;17(10):1346. https://doi.org/10.3390/ph17101346

23. A comprehensive review on transdermal patches as an efficient approach for the delivery of drug. Polymer-Plastic Technology and Materials. 2024;63(8):1045–1069. doi:10.1080/25740881.2024.2317408.

24. Transdermal Drug Delivery Systems: A Focused Review of the Physical Methods of Permeation Enhancement. Review article. Available through PubMed Central.

25. Crasta A, Painginkar T, Sreedevi A, et al. Transdermal drug delivery system: A comprehensive review of innovative strategies, applications, and regulatory perspectives. OpenNano. 2025;24.100245. doi:10.1016/ j. onano.2025.100245.

26. Raghav RS, Verma S, Monika. A comprehensive review on potential chemical and herbal permeation enhancers used in transdermal drug delivery systems. Recent Advances in Drug Delivery and Formulation. 2024;18(1):21–34. DOI: 10.2174/0126673878272043240114123908.

27. Vaseem RS, D'cruz A, Shetty S, et al. Transdermal Drug Delivery Systems: A Focused Review of the Physical Methods of Permeation Enhancement. Advanced Pharmaceutical Bulletin. 2024;14(1):67–85. doi:10.34172/apb.2024.018.

28. Safety Problems With a Transdermal Patch for Migraine

Loder EW, Rayhill M, Burch RC. Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. Headache. 2018;58(10):1639–1657. https://doi.org/10.1111/head.13424

29. Ronnander P, Simon L, Spilgies H, Koch A, Scherr S. Dissolving polyvinylpyrrolidone-based microneedle systems for in-vitro delivery of sumatriptan succinate. European Journal of Pharmaceutical Sciences. 2018;114: 84–92. doi:10.1016/ j. ejps.2017.11.031.

30. Kathe K, Kathpalia H. Film forming systems for topical and transdermal drug delivery. Asian Journal of Pharmaceutical Sciences. 2017;12(6):487–497. DOI: 10.1016/j.ajps.2017.07.004.

31. Sivadasan D, Madkhali OA. The Design Features, Quality by Design Approach, Characterization, Therapeutic Applications, and Clinical Considerations of Transdermal Drug Delivery Systems—A Comprehensive Review. Pharmaceuticals. 2024;17(10):1346. DOI: 10.3390/ph17101346

32. Kushwaha R, Palei NN. Transdermal Drug Delivery Systems: Different Generations and Dermatokinetic Assessment of Drug Concentration in Skin. Pharmaceutical Medicine. 2024;38:407–427.
DOI: 10.1007/s40290-024-00537-8.

33. Long-acting transdermal drug delivery formulations: Current developments and innovative pharmaceutical approaches. Advanced Drug Delivery Reviews. 2024. DOI: 10.1016/j.addr.2024.115326